Cargando…

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children

Probability of target attainment is the key factor influencing the outcome of meropenem therapy. The objective of the present study was to evaluate the relationship between the time in which the plasma free concentration of meropenem exceeds the minimum inhibitory concentration of pathogens (fT (>...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zeming, Bi, Jing, You, Dianping, Tang, Yu, Liu, Gang, Yu, Jinqian, Jin, Zhipeng, Jiang, Tingting, Tian, Xue, Qi, Hui, Dong, Lei, Dong, Lili, Zhang, Qunqun, Zhao, Wei, Shen, Adong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581397/ https://www.ncbi.nlm.nih.gov/pubmed/36278190 http://dx.doi.org/10.3389/fphar.2022.961863

Ejemplares similares

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Meropenem for children with severe pneumonia: Protocol for a randomized controlled trial
por: Tian, Xue, et al.
Publicado: (2022)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2021)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
por: Yang, Nan, et al.
Publicado: (2022)

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
por: Gijsen, Matthias, et al.
Publicado: (2022)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
por: Gijsen, Matthias, et al.
Publicado: (2021)

Initial therapeutic target attainment of perampanel in pediatric patients with epilepsy
por: Yu, Lingyan, et al.
Publicado: (2023)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
por: Zylbersztajn, Brenda, et al.
Publicado: (2021)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
por: Deng, Guoliang, et al.
Publicado: (2023)

Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery
por: Lu, Cheng, et al.
Publicado: (2016)

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate
por: Wu, Yue-E, et al.
Publicado: (2020)

Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support
por: Wang, Yixue, et al.
Publicado: (2021)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
por: Trang, M., et al.
Publicado: (2021)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
por: Sime, Fekade B., et al.
Publicado: (2018)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
por: Zyryanov, Sergey, et al.
Publicado: (2023)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
por: Ehmann, Lisa, et al.
Publicado: (2017)

2560. Individual Meropenem Epithelial Lining Fluid and Plasma PK/PD Target Attainment in Patients with Pneumonia
por: Rohani, Roxane, et al.
Publicado: (2023)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Biased computation of probability of target attainment for antimicrobial drugs
por: Toutain, Pierre‐Louis, et al.
Publicado: (2023)

Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients
por: de Velde, Femke, et al.
Publicado: (2021)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits
por: Egbelowo, Oluwaseun, et al.
Publicado: (2021)

Case Report: Subtherapeutic Vancomycin and Meropenem Concentrations due to Augmented Renal Clearance in a Patient With Intracranial Infection Caused by Streptococcus intermedius
por: Fransson, Marcus, et al.
Publicado: (2021)

Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020
por: Dräger, Sarah, et al.
Publicado: (2023)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

The application of antimicrobials in VAP patients requiring ECMO supportive treatment
por: Zou, Dongna, et al.
Publicado: (2022)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized With COVID-19 in Leishenshan Hospital, Wuhan, China
por: Li, Jinpeng, et al.
Publicado: (2020)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

Allyl methyl trisulfide protected against LPS-induced acute lung injury in mice via inhibition of the NF-κB and MAPK pathways
por: Wang, Shuo, et al.
Publicado: (2022)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
por: Wu, Yue-E, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6mvqaptjafdjmd75ghoqo55u5f